Read the article here
- Media
The Times Magazine : Brenus Pharma Secures $25 Million to Propel Clinical Trials for Precision Cancer Vaccines
Menu
Read the article here
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
